| Metric | This Period | Prior Year Period | YoY |
|---|---|---|---|
| Revenue / Net Sales | ¥6303.4B | ¥5828.4B | +8.2% |
| Operating Income / Operating Profit | ¥1262.9B | ¥1244.2B | +1.5% |
| Profit Before Tax (税引前利益) | ¥1302.3B | ¥1133.7B | +14.9% |
| Net Income / Net Profit | ¥993.0B | ¥859.7B | +15.5% |
| ROE | 3.1% | 2.8% | - |
FY2026 Q1 results: Revenue ¥6,303.4B (YoY +¥475.0B +8.2%), Operating Income ¥1,262.9B (YoY +¥18.7B +1.5%), Quarterly Net Income attributable to owners of the parent ¥983.5B (YoY +¥133.5B +15.7%). The core Pharmaceuticals business accounted for 72% of revenue and drove an +8.6% increase, but Operating Income decreased by -0.9%. SG&A increased by +11.6% YoY, outpacing revenue growth and reducing the operating margin to 20.0% (from 21.3%, -1.3pt). Meanwhile, a large improvement in financial results (financial expense reduced from ¥137.5B to ¥20.4B; financial income increased from ¥26.9B to ¥59.8B) drove Profit Before Tax to a strong +14.9% increase, and the bottom line finished with double-digit net income growth.
[Revenue] Revenue was ¥6,303.4B (YoY +8.2%). By segment, Pharmaceuticals (Medical-related business) was ¥4,538.2B (+8.6%), constituting 72.0% of the total; Nutraceuticals-related business was ¥1,389.2B (+5.8%) at 22.0%; Other businesses were ¥296.8B (+12.9%) at 4.7%; Consumer-related business was ¥79.2B (+7.3%) at 1.3%. Increased sales of therapeutic drugs and infusion products in the core Pharmaceuticals segment and double-digit growth in Other businesses drove revenue growth. Gross margin slightly declined to 72.4% (from 73.1%, -0.7pt) but remained at a high level.
[Profitability] Operating Income was ¥1,262.9B (YoY +1.5%), lagging revenue growth significantly. SG&A was ¥2,594.9B (+11.6%), increasing 3.4pt faster than revenue and raising the SG&A ratio to 41.2% (from 39.9%, +1.3pt). R&D expenses were also robust at ¥821.0B (+4.7%) (R&D to sales ratio 13.0%). As a result, operating margin declined to 20.0%. Non-operating items saw a dramatic improvement: financial expense ¥20.4B (from ¥137.5B, -85.2%), financial income ¥59.8B (from ¥26.9B, +122.3%), and equity-method investment income ¥83.6B, expanding Profit Before Tax to ¥1,302.3B (+14.9%). After deducting corporate taxes of ¥309.3B, Quarterly Net Income was ¥992.9B (+15.5%), with Net Income attributable to owners of the parent ¥983.5B (+15.7%), achieving double-digit net income growth at the bottom line. In conclusion, cost increases offset revenue momentum at the operating level, but improvement in financial results secured overall revenue and earnings growth.
The Pharmaceuticals segment achieved revenue of ¥4,538.2B (+8.6%) but Operating Income slightly decreased to ¥1,155.0B (-0.9%). Margin was 25.4% (from 25.5%, -0.1pt), suggesting increased promotional and distribution costs. The Nutraceuticals-related business reported revenue ¥1,389.2B (+5.8%) and Operating Income ¥157.8B (+1.3%), with a margin of 11.4%, roughly flat. The Consumer-related business had revenue ¥79.2B (+7.3%) and Operating Income ¥56.4B (+8.7%), maintaining an extremely high margin of 71.3%. Other businesses posted revenue ¥296.8B (+12.9%) and Operating Income ¥29.2B (+62.6%), improving margin to 9.9% with significant profit growth. Consolidated Operating Income after deducting corporate-level expenses of ¥155.2B was ¥1,262.9B. The slight profit decline in Pharmaceuticals contributed to overall margin compression, but Other businesses compensated and the group secured overall profit growth.
[Profitability] Operating margin 20.0% (prior 21.3%), Net margin 15.8% (prior 14.8%). While operating margin declined, improvement in financial results lifted the bottom-line margin. ROE was 3.1%, a low level (roughly flat based on prior-year estimate). Gross margin of 72.4% remains well above industry averages. R&D-to-sales ratio 13.0% is slightly conservative versus pharmaceutical industry norms (15–20%). [Cash Quality] Operating Cash Flow (OCF) ¥1,088.8B versus Net Income ¥993.0B gives an OCF/Net Income ratio of 1.10x, which is healthy. Working capital movements: Inventories increased ¥135.0B, Trade receivables decreased ¥386.7B, and Trade payables decreased ¥253.6B, offsetting each other. Inventory turnover days are 817 days, indicating significant room for inventory efficiency improvement. [Investment Efficiency] Total asset turnover annualized about 0.60x (quarterly sales ¥6,303.4B ×4 ÷ Total assets ¥42,091.9B). Equity-method investment balance ¥3,663.0B produced equity-method income ¥83.6B, a contribution rate of 2.3%. [Financial Strength] Equity Ratio 73.8% (prior 72.3%), D/E ratio 0.33x (interest-bearing debt ¥948.2B ÷ Net assets ¥3,174.0B), indicating very strong balance sheet. Current ratio 233.2% (Current assets ¥16,002B ÷ Current liabilities ¥6,861B), cash and deposits ¥5,383.0B sufficiently cover short-term liabilities. Interest coverage approximately 115.1x (Operating Income ¥1,262.9B ÷ interest payments ¥11.0B).
Operating Cash Flow was ¥1,088.8B (YoY +3.3%), generated from Profit Before Tax ¥1,302.3B and a pre-working-capital subtotal of ¥1,403.7B. In working capital, a decrease in trade receivables of ¥386.7B contributed positively, while inventory increase ¥135.0B and decrease in trade payables ¥253.6B were headwinds. After corporate tax payments of ¥344.0B, OCF totaled ¥1,088.8B. Investing Cash Flow was -¥224.0B, driven by capital expenditures ¥251.6B and intangible asset investments ¥81.4B, partially offset by proceeds from sale of tangible fixed assets ¥30.1B and decrease in time deposits ¥97.0B. Free Cash Flow was ¥864.9B, ample. Financing Cash Flow was -¥846.2B, with major outflows including redemption of bonds ¥300.0B, dividend payments ¥375.0B, and share buybacks ¥84.4B; short-term borrowings decreased net ¥15.5B. Cash and cash equivalents rose slightly from ¥5,346.5B at the beginning of the period to ¥5,383.0B at period-end after ¥17.9B of foreign exchange effects. OCF/Net Income ratio 1.10x and FCF/Net Income ratio 0.87x indicate a healthy cash generation profile.
Against Operating Income ¥1,262.9B, financial results comprised financial income ¥59.8B and financial expense ¥20.4B, a net positive contribution of ¥39.4B; equity-method income ¥83.6B; other income ¥43.3B less other expenses ¥7.7B, leading to Profit Before Tax ¥1,302.3B. The large improvement in financial results (prior-year financial expense ¥137.5B, net negative contribution of ¥110.6B) is attributable to reduced interest payments from bond redemptions and increased deposit interest, and can be viewed as structural improvement. Conversely, impairment losses ¥2.9B were recorded in operating expenses, slightly pressuring recurring earnings. Comprehensive income was ¥1,207.6B, ¥214.6B above Net Income ¥993.0B; the main driver of other comprehensive income ¥214.7B was foreign currency translation gains on overseas operations ¥236.2B (large improvement from prior -¥658.9B), reflecting favorable FX. Remeasurement of defined benefit plans added ¥1.0B, while fair value decreases on financial assets -¥26.1B partly offset. OCF is roughly at the same level as Net Income, and excluding working capital movements, the cash realization of earnings is good. The recurring earnings base is established at the operating level, and if the financial results improvement is not temporary, the quality of earnings can be assessed as high.
Full Year guidance: Revenue ¥2,520.0B (Q1 progress 25.0%), Operating Income ¥360.0B (Q1 progress 35.1%), Net Income attributable to owners of the parent ¥265.0B (Q1 progress 37.1%). At Q1, Operating Income and Net Income progress both exceed 35%, suggesting the guidance is conservatively set. Dividend forecast remains at ¥70 per share, unchanged with no revision at Q1. The full-year Operating Income outlook implies a large YoY decline of -24.9%, but given Q1 Operating Income +1.5% YoY, the company may be anticipating significant one-off expenses or worsening business conditions in H2. Net Income guidance of -27.0% YoY versus Q1 +15.7% YoY also shows a large divergence and a cautious posture. Depending on H2 progress, there may be room for upward revisions, but downside risks such as continued slight profit decline in Pharmaceuticals and sustained high SG&A should be monitored.
Full-year dividend forecast ¥70 (unchanged from prior ¥70), implying a payout ratio of 13.9% against full-year EPS forecast ¥504.94, which is very conservative. Based on Q1 EPS ¥186.31 annualized to approx. ¥745, a ¥70 dividend implies a payout ratio around 9.4%, even lower. Q1 dividend payments were ¥375.0B and share buybacks ¥84.4B, totaling shareholder returns ¥459.4B. Total return ratio versus Free Cash Flow ¥864.9B is 53.1%, a comfortably funded level. With cash and deposits ¥5,383.0B and Equity Ratio 73.8% plus annual OCF (estimated from prior-year results at over ¥4,000B), dividend sustainability is very high and there is ample room for potential dividend increases. Past dividend track record regarding consecutive increases is unclear, but current payout levels suggest scope to strengthen shareholder returns. Treasury stock increased to ¥933B (prior ¥852B), and buybacks continue as part of total returns.
Inventory Efficiency Risk: Inventories ¥3896.8B, +4.1% YoY, with inventory days 817 days—extremely long. Increased production and safety stock reduced OCF by ¥135.0B; if supply-demand adjustment lags or obsolescence/disposal risk materializes, additional impairments or discount selling could pressure profits. Even considering the long inventory cycles typical in pharmaceuticals, inventory optimization is an urgent issue.
SG&A Control Risk: SG&A ¥2,594.9B, +11.6% YoY, outpacing revenue growth +8.2% by 3.4pt. SG&A ratio rose to 41.2% (from 39.9%), compressing operating margin by 1.3pt. The increase is presumed driven by intensified promotion and distribution in Pharmaceuticals; if this trend continues, operating leverage will deteriorate and structural profitability could weaken. Scrutiny and control of cost-effectiveness are required.
Business Concentration Risk: High concentration with Pharmaceuticals accounting for 72% of revenue and the bulk of Operating Income. Pharmaceuticals Operating Income was already -0.9% YoY, and factors like patent expirations, drug price revisions, or generic entry could exert significant downward pressure on consolidated results. A somewhat conservative R&D ratio of 13.0% also suggests potential mid-to-long-term pipeline depletion risk.
Profitability & Return
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Operating Margin | 20.0% | – | – |
| Net Margin | 15.8% | – | – |
Industry positioning data are limited, but Operating Margin 20.0% indicates profitability above typical pharmaceutical industry levels.
Growth & Capital Efficiency
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Revenue Growth (YoY) | 8.2% | – | – |
Revenue growth 8.2% reflects solid demand expansion in core markets, though relative position within the industry cannot be assessed.
※ Source: Company aggregation
Improvement in financial results materially boosted bottom-line profit. Reduced interest payments from bond redemptions (financial expense from ¥137.5B → ¥20.4B) and increased deposit interest improved financial results by over ¥150B net, supporting a +14.9% increase at the Profit Before Tax level. If this structural improvement continues, it could offset operating margin declines and sustain double-digit net income growth.
Q1 progress versus full-year guidance shows Operating Income 35.1% and Net Income 37.1%, ahead of schedule. Given that guidance implies full-year Operating Income -24.9% and Net Income -27.0% declines, there is room for upward revision. However, the slight profit decline in Pharmaceuticals and rising SG&A trends are H2 downside risks that warrant monitoring.
Financial strength and shareholder return capacity stand out. Equity Ratio 73.8%, cash and deposits ¥5,383.0B, FCF ¥864.9B versus total returns ¥459.4B (total return ratio 53.1%), and payout ratio 13.9% are very conservative. If inventory efficiency improves and SG&A is controlled, cash generation could increase further, expanding resources for dividend increases and buybacks.
This report was automatically generated by AI analyzing XBRL earnings disclosure data. It does not constitute a recommendation to invest in any particular security. Industry benchmarks are reference information compiled by our firm based on public financial statements. Investment decisions are your responsibility; consult a professional advisor if necessary.